Revamp Medical

Here is a fact about the human circulatory system that turns out to matter enormously to hospital budgets: when the heart starts to fail, the kidneys often fail first, and not because anything is wrong with the kidneys. They are simply drowning. Blood backs up, venous pressure climbs, and the organs that are supposed to bail fluid out of the body find themselves working against a rising tide. Doctors respond by prescribing diuretics - drugs that tell the kidneys to make more urine - and in a great many patients the drugs simply stop working. This is called diuretic resistance, and it is one of those unglamorous clinical problems that kills people and costs money in roughly equal measure.

Revamp Medical, a company of about fifteen people founded in Netanya, Israel in 2016, has built its entire existence around this one problem. Its product is the Doraya catheter, and the pitch is refreshingly literal. Instead of adding more drugs, or escalating to dialysis, or attempting anything permanent, you thread a catheter into the inferior vena cava - the big vein that returns blood to the heart - and park an adjustable flow regulator just below where the renal veins connect. For up to twelve hours it gently reduces the pressure the kidneys are fighting against. The theory is that if you lower the pressure, the diuretics start working again, the patient offloads the fluid, and then you remove the device entirely. Nothing is left behind.

It is worth pausing on how contrarian that last part is. Most of the celebrated devices in cardiology are implants - valves, stents, pacemakers, things engineered to survive inside a body for a decade or more. The engineering prestige goes to permanence. Revamp went the other way. The Doraya's defining feature is that it comes out, which means the company traded the recurring-revenue romance of an implant for something a hospital can actually schedule around a shift change. In medicine, an exit strategy is a feature, and Revamp treats it like one.

The clinical language for what Doraya does is "interventional decongestion," and it targets what the company calls the local mechanism of diuretic resistance rather than the systemic one. That distinction is the whole company. Cardiologists who have used it seem to appreciate the restraint. "The elegance of this approach," one advanced heart failure specialist put it, "is that it addresses the local mechanism for diuretic resistance rather than apply the brute force of systemic drugs or dialysis." When your customers describe your product using the word "elegance," you are probably onto something.

Acute heart failure does not sound like a venture-scale opportunity until you look at the arithmetic. Roughly a million Americans are hospitalized with it every year. Somewhere between fifteen and twenty percent of them respond poorly or slowly to standard diuretic therapy. And about one in four are readmitted within thirty days - a statistic that has become financially radioactive since the Affordable Care Act started penalizing hospitals for it. Poor decongestion, in other words, is not just a medical failure. It is a line item.

This is the disguise: a market that looks like a niche cardiology procedure is really a bet on hospital economics. If a twelve-hour catheter can shorten a stay and prevent a readmission, it pays for itself in the ledger before it does anything for the patient - and it does plenty for the patient. That dual payoff is what lets a small Israeli company argue that a modest device addresses a very large problem. As one physician bluntly told the company, "regardless of reimbursement changes or country-specific idiosyncrasies, effective and durable decongestion will always be at the heart of profitable HF treatment." He is describing a market that does not go away.

The thing that makes investors comfortable with a fifteen-person company attacking a hard clinical problem is usually the resume, and Revamp's is unusually deep. Co-founder and CTO Rafi Benary has done this before - repeatedly. He co-founded Ventor Technologies, a cardiac valve catheter company that Medtronic acquired for $300 million in 2013, and was the founding CEO and CTO of EndoSpan. When a serial cardiovascular founder with a nine-figure exit tells you he sees an unmet need, that is a signal that costs nothing to notice.

Co-founder and board member Lihu Avitov brings the operational and commercial side, having run Angioslide, a cardiovascular company with both CE and FDA marketing approvals that shipped thousands of catheters into the US, EU, China and India. And in March 2024 the company added a marquee chief executive: Mike Favet, who had most recently been CEO of NeuroPace, which he took public in 2021, and before that a managing director at KCK Medtech - the same firm that would go on to lead Revamp's Series A. Favet leaving a public company to run a startup in Netanya is the kind of career move that only makes sense if you believe the technology is real.

Rounding out the team are COO Yael Shohat, a Technion-trained biomedical engineer with a decade of cardiac R&D behind her at companies like V-Wave and EndoCross; clinical director Sahar Boostenay; and operations-and-engineering lead Offer Razi. It is, by design, a small band of people who have each shipped complex cardiovascular devices before - which is a polite way of saying nobody here is learning on the job.

Regulators noticed early. In July 2020 the FDA granted the Doraya catheter Breakthrough Device designation, a status reserved for technologies that address life-threatening conditions and that the agency agrees to review on an expedited basis. It is not approval, and it is important not to confuse the two - Doraya remains an investigational device working through clinical trials. But it is a meaningful nod, and it changed the company's roadmap.

The evidence started arriving next. First-in-human feasibility data was presented at THT 2022 and published in the Journal of the American College of Cardiology: Basic to Translational Science that March - the peer-reviewed currency that actually persuades cardiologists. Later that year the company enrolled its first patient in the U.S. DORAYA-HF Early Feasibility Study. Then, in 2023, it closed a Series A preferred financing led by KCK Medtech, with existing backers Arkin and Accelmed participating alongside investor Michael Berman. Earlier development had also drawn a European Union Horizon 2020 SME Instrument grant. It is a funding stack that spans Tel Aviv venture money and Brussels innovation policy, which is a fairly Israeli-medtech thing to be.

What Revamp has not done is overpromise. There is no commercial launch date being waved around, no revenue being projected into a hockey stick. The company is doing the slow, expensive, unavoidable work of proving a device is safe and effective before selling it - which, for a thing you put inside a sick person's vena cava, is the only responsible order of operations.